Doximity (NYSE:DOCS) Shares Up 8% – Should You Buy?

Doximity, Inc. (NYSE:DOCS)’s share price rose 8% during mid-day trading on Tuesday. The company traded as high as $34.01 and last traded at $33.9640. 1,256,274 shares were traded during mid-day trading, a decline of 68% from the average daily volume of 3,965,258 shares. The stock had previously closed at $31.45.

Doximity News Roundup

Here are the key news stories impacting Doximity this week:

• Positive Sentiment: Doximity partnered with Wolters Kluwer Health to make evidence-based content from UpToDate available through Doximity Ask, its AI clinical decision-support tool. The integration is expected to provide clinicians at participating health systems with answers based on approximately 13,000 UpToDate topics and best-practice guides. The deal could improve Ask’s clinical usefulness, support adoption among health systems and strengthen Doximity’s position in healthcare AI, although financial terms were not disclosed. Doximity and Wolters Kluwer Sign Partnership to Bring UpToDate to Doximity Ask
• Neutral Sentiment: Multiple law firms reiterated that investors in Doximity shares purchased between August 8, 2024, and May 13, 2026, may seek appointment as lead plaintiff by November 16, 2026. These announcements largely repeat existing litigation information rather than introducing a new operational development, but they keep the lawsuit in focus for investors. Rosen Doximity investor deadline notice
• Negative Sentiment: The securities lawsuit alleges that Doximity overstated the contribution of its Newsfeed advertising product to revenue growth, relied on “light engagement” ad formats it had publicly disavowed and misstated its competitive position. The complaint claims investors suffered losses following several sharp share-price declines. The allegations have not been established in court, but potential litigation costs, regulatory scrutiny and questions about advertising-growth quality represent an overhang for DOCS. Doximity securities class action investor alert

Wall Street Analysts Forecast Growth

A number of research firms have weighed in on DOCS. Piper Sandler restated an “overweight” rating and issued a $47.00 price target (up from $42.00) on shares of Doximity in a research note on Friday, August 7th. Freedom Capital downgraded shares of Doximity from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, September 8th. Citigroup downgraded shares of Doximity to an “underperform” rating in a research report on Monday, June 29th. Truist Financial boosted their price objective on Doximity from $19.00 to $24.00 and gave the stock a “hold” rating in a report on Thursday, August 13th. Finally, Barclays upped their target price on Doximity from $20.00 to $27.00 and gave the company an “equal weight” rating in a research report on Friday, August 21st. Eight research analysts have rated the stock with a Buy rating, fourteen have issued a Hold rating and three have issued a Sell rating to the company’s stock. According to data from MarketBeat.com, Doximity currently has a consensus rating of “Hold” and an average price target of $30.73.

Doximity Stock Performance

The stock’s fifty day moving average price is $26.87 and its two-hundred day moving average price is $23.69. The company has a market cap of $6.01 billion, a P/E ratio of 39.69, a P/E/G ratio of 24.22 and a beta of 1.22.

Doximity (NYSE:DOCS) last issued its earnings results on Thursday, August 6th. The company reported $0.29 earnings per share for the quarter, beating analysts’ consensus estimates of $0.16 by $0.13. The firm had revenue of $156.62 million for the quarter. Doximity had a return on equity of 18.06% and a net margin of 25.48%. The company’s revenue for the quarter was up 7.3% compared to the same quarter last year. During the same period in the prior year, the business posted $0.36 EPS. On average, equities research analysts forecast that Doximity, Inc. will post 0.74 EPS for the current year.

Insider Activity at Doximity

In related news, CAO Siddharth Sitaram sold 2,613 shares of the stock in a transaction that occurred on Wednesday, October 14th. The shares were sold at an average price of $30.68, for a total value of $80,166.84. Following the completion of the transaction, the chief accounting officer owned 101,432 shares of the company’s stock, valued at $3,111,933.76. This represents a 2.51% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, Director Kira Wampler sold 2,000 shares of the firm’s stock in a transaction that occurred on Thursday, October 1st. The shares were sold at an average price of $28.91, for a total transaction of $57,820.00. Following the completion of the sale, the director owned 27,923 shares in the company, valued at $807,253.93. This represents a 6.68% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 19,250 shares of company stock worth $613,855 in the last 90 days. 31.80% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On Doximity

A number of institutional investors and hedge funds have recently bought and sold shares of DOCS. Versant Capital Management Inc boosted its stake in shares of Doximity by 1,176.9% during the third quarter. Versant Capital Management Inc now owns 1,826 shares of the company’s stock valued at $52,000 after purchasing an additional 1,683 shares in the last quarter. Fortitude Family Office LLC increased its stake in shares of Doximity by 31,271.4% in the third quarter. Fortitude Family Office LLC now owns 2,196 shares of the company’s stock valued at $62,000 after buying an additional 2,189 shares during the period. Parallel Advisors LLC increased its stake in shares of Doximity by 111.0% in the first quarter. Parallel Advisors LLC now owns 2,560 shares of the company’s stock valued at $60,000 after buying an additional 1,347 shares during the period. EverSource Wealth Advisors LLC raised its holdings in Doximity by 937.7% in the 1st quarter. EverSource Wealth Advisors LLC now owns 2,833 shares of the company’s stock valued at $66,000 after buying an additional 2,560 shares during the last quarter. Finally, Leonteq Securities AG raised its holdings in Doximity by 65.6% in the 1st quarter. Leonteq Securities AG now owns 2,912 shares of the company’s stock valued at $68,000 after buying an additional 1,154 shares during the last quarter. Institutional investors and hedge funds own 87.19% of the company’s stock.

Doximity Company Profile

Doximity, Inc operates a digital platform designed for medical professionals in the United States. Its network connects physicians, nurse practitioners, physician assistants, pharmacists and other healthcare professionals, providing tools for professional communication, collaboration and career development.

The company offers services including secure messaging, telehealth, digital faxing, physician scheduling and professional networking. Doximity also provides medical news and educational content, as well as recruiting and job-search resources for healthcare professionals.

Doximity generates additional revenue through digital marketing and engagement solutions for pharmaceutical companies, healthcare organizations and health systems.